rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

MediciNova, Inc.

MNOV · Nasdaq

Health CareBiotechnologyNot moving yet

MNOV stood above a rising 150-day average in 19 of the last 52 weekly readings, and has been out of that trend for the last 1 week. It is 7.2% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

SEC filings

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 1
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$3.5M
Officials’ trades on record
0
Institutions holding
29 (+1)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 19 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$3.3M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months2
Buyers · sellers0 · 2
WhoDidSharesTraded
3d Investment Partners Pte. Ltd.Othersold640,000at $2.7025 Sep 2026filed 29 Sep 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders29+1 on the quarter
New · exited4 · 3
Reported value$6.9M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Essex Woodlands Management, Inc.unchanged · filed 4 Aug 20261,105,941$1.5M00.0%
BlackRock, Inc.added · filed 7 Aug 2026752,091$993K+46,137+6.5%
CITIGROUP INCunchanged · filed 3 Aug 2026635,715$839K00.0%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 2026609,052$804K-1,987−0.3%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026539,312$712K-4,531−0.8%
VANGUARD FIDUCIARY TRUST COadded · filed 13 Aug 2026282,608$373K+1,987+0.7%
UBS Group AGunchanged · filed 13 Aug 2026222,200$293K00.0%
RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 2026205,400$271K+15,500+8.2%
STATE STREET CORPunchanged · filed 7 Aug 2026193,698$256K00.0%
NORTHERN TRUST CORPadded · filed 13 Aug 2026143,665$190K+10,502+7.9%
31 Mar 2023 – 30 Jun 2026
212631Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

3D Investment Partners Pte. Ltd. Company insiderOther · last 25 Sep 20260 · 1
3d Opportunity Master Fund Company insiderOther · last 25 Sep 20260 · 1
Carolyn Beaver Company insiderDirector · last 23 Jun 20260 · 0
Hideki Nagao Company insiderDirector · last 23 Jun 20260 · 6
Nicole Lemerond Company insiderDirector · last 23 Jun 20260 · 0
Kazuko Matsuda Company insiderChief Medical Officer · last 16 Jan 20262 · 0
Yuichi Iwaki Company insiderPresident and CEO · last 16 Jan 202615 · 0
Geoffrey Obrien Company insiderVice President · last 9 Jan 20240 · 1
Federico C.a. Gaeta Company insiderChief Scientific Officer · last 22 Apr 20210 · 0
Yutaka Kobayashi Company insiderDirector · last 16 Jun 20209 · 0
Yoshio Ishizaka Company insiderDirector · last 10 Jun 20192 · 0
Masatsune Okajima Company insiderVP and Head of Japanese Office · last 28 Feb 20190 · 0

Same industry

MRNA ModernaLeading+154%
IOVA Iovance BiotherapeuticsLeading+133%
ABCL AbCellera BiologicsLeading+61%
ENTX Entera BioLeading+49%
HALO Halozyme TherapeuticsLeading+46%
XERS Xeris Biopharma HoldingsLeading+46%
HELP Helus PharmaLeading+37%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-31.8%
Share count trendFY 2025 · to 5 Mar 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$30.8M
Free cash flowFY 2025 · to 31 Dec 2025−$9.8M

Analyst forecasts

No analyst forecasts yet.